nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

01.02.2016

Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants

verfasst von: Jack E. Ansell

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Although there is controversy about the absolute need for a reversal agent for the new direct oral anticoagulants (DOACs), the absence of such an agent is a barrier to more widespread use of these agents. For the management of major life-threatening bleeding with the DOACs, most authorities recommend the use of four factor prothrombin complex concentrates, although the evidence to support their use in terms of improving outcomes is meager. At the present time, there are three antidotes in development and poised to enter the market. Idarucizumab is a drug-specific antidote targeted to reverse the direct thrombin inhibitor, dabigatran. Andexanet alfa is a class-specific antidote targeted to reverse the oral direct factor Xa inhibitors as well as the indirect inhibitor, enoxaparin. Ciraparantag is a universal antidote targeted to reverse the direct thrombin and factor Xa inhibitors as well as the indirect inhibitor, enoxaparin.

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1964129-33f4-4e4e-86e3-8e6a4e65bd83. Accessed 8 Mar 15

Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (2008) The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines. Chest 133:160S–198SCrossRefPubMed

Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e24S–e43SPubMedCentralCrossRefPubMed

Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis: American college of chest physicians evidence-based clinical practice guidelines. Chest J 141(2_suppl):e120S–e151SCrossRef

Roldan V, Marin F (2012) Pro: antidote for new anticoagulants—specific target of inhibition requires a specific target for neutralisation. Thromb Haemost 108:621–622CrossRefPubMed

Eerenberg ES, Levi M, Buller HR (2012) Contra: antidotes for novel anticoagulants—do we really need them. Thromb Haemost 108:623–624CrossRefPubMed

Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S (2013) Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 128:2325–2332CrossRefPubMed

Piccini JP, Garg J, Patel MR, Lokhnygina Y, Goodman SG, Becker RC, Berkowitz SD, Breithardt G, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Mahaffey KW, Singer DE, Califf RM, Fox KAA (2014) Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 35:1873–1880CrossRefPubMed

Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S (2014) Reversal agents in development for the new oral anticoagulants. Postgrad Med 126:19–24CrossRefPubMed

10.

Miller MP, Trujillo TC, Nordenholz KE (2014) Practical considerations in emergency management of bleeding in the setting of target-specific oral anticoagulants. Am J Emerg Med 32:375–382CrossRefPubMed

11.

Jackson LR, Becker RC (2014) Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. J Thromb Thrombolysis 37:380–391CrossRefPubMed

12.

Siegal DM (2015) Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis 39:395–402CrossRefPubMed

13.

Dickneite G, Hoffman M (2014) Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost 111:189–198CrossRefPubMed

14.

Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M (2011) Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 124:1573–1579CrossRefPubMed

15.

Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G (2012) Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. Thromb Haemost 108:217–224CrossRefPubMed

16.

Zahir H, Brown KS, Vandell A, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM (2014) Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 131:82–90CrossRefPubMed

17.

Kaatz S, Kouides PA, Garcia DA, Spyropoulos AC, Crowther M, Douketis JD, Chan AKC, James A, Moll S, Ortel TL, van Cott EM, Ansell J (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol 87:S141–S145CrossRefPubMed

18.

Miesbach W, Seifried E (2012) New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. Thromb Haemost 108:625–632CrossRefPubMed

19.

Schiele F, van Ryn J, Canada K, Newsome C, Sepuveda E, Park J, Nar J, Litzenburger T (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554–3562CrossRefPubMed

20.

Glund S, Stangier J, Schmohl M, De Smet M, Gansser D, Lang B, Moschetti V, Ramael S, Reilly PA (2013) A specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers. Circulation 128:A17765

21.

Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kapmhusien PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373:511–520CrossRefPubMed

22.

Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19:446–451CrossRefPubMed

23.

Gold AM, Crowther M, Levy G, Lu G, Leeds J, Barron L, Conley P, Castillo J, Curnutte J, Connolly S (2015) ANNEXA-R: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subject by andexanet alfa, a universal antidote for factor Xa inhibitors. J Am Coll Cardiol 65:abst 23

24.

Crowther M, Levy GG, Lu G, Leeds J, Barron L, Conley PB, Castillo J, Curnutte JT, Connolly S (2014) ANNEXA-A: a phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa, a universal antidote for factor Xa inhibitors. Circulation 130:2116

25.

Crowther M, Gold A, Lu G, Leeds J, Wiens B, Mathur V, Castillo J, Conley P, Connolly S, Curnutte J (2015) ANNEXA-A part 2: a phase 3 randomized, double-blind, placebo-controlled trial demonstrating sustained reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa, a universal antidote for factor Xa inhibitors. J Thromb Hemost 13(suppl. 2):84–85

26.

Laulicht B, Bakhru S, Jiang X, Chen L, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S (2013) Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. Presented at the 24th congress of the international society on thrombosis and haemostasis, Amsterdam, June29–July 4, 2013. Abstract (http://www.eventure-online.com/eventure/publicAbstractView.do?id=226718&congressId=6839)

27.

Bakhru S, Laulicht B, Jiang X, Chen I, Pan D, Grosso M, Morishima Y, Brown K, Masumoto H, Costin J, Steiner S (2013) PER977: a synthetic small molecule which reverses over-dosage and bleeding by the new oral anticoagulants. Circulation 128:A18809

28.

Bakhru S, Laulicht B, Jiang X, Chen L, Grosso M, Morishima Y, Brown K, Mercuri M, Masumoto H, Costin J, Steiner S (2014) Reversal of anticoagulant-induced bleeding in external and internal bleeding models by PER977, a small molecule anticoagulant antidote. Circulation 130:A19361

29.

Ansell JE, Bakhru S, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Eng J Med 339:2141–2142CrossRef

30.

Ansell J (2015) Is there a need for an alternative in the era of novel anticoagulants? Exp Rev Cardiovasc Ther. doi:10.1586/14779072.2015.1069707

Titel: Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants
verfasst von: Jack E. Ansell
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 2/2016
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-015-1288-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents

Who, when, and how to reverse non-vitamin K oral anticoagulants

Hypercoagulable state evaluated by thromboelastography in patients with idiopathic membranous nephropathy

Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism

Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication